|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0280 - 0.0349|
|52 Week Range||0.0100 - 0.0900|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ORLANDO, Fla., March 26, 2018-- via OTC PR WIRE-- Immune Therapeutics, Inc., a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment ...
ORLANDO, Fla., Feb. 20, 2018-- via OTC PR WIRE-- Immune Therapeutics, Inc., a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies for the treatment ...
The lack of revenue from Nigeria after obtaining approval has been major concern to shareholders and also to the company. The company's distribution agreement is being modified which caused a delay in shipping product and realization of revenue.
Omaera will supply Lodonal to patients exclusively in Kenya, where 5.9% of the country's 47 million population live with HIV/AIDS. Omaera Territory includes six countries: Republic of Kenya, Republic of Uganda United Republic of Tanzania, Republic of Burundi and Republic of Rwanda. Omaera was launched in 1993 as a locally owned wholesaling operation that has grown into one of the most recognized medical supply and distribution companies in East Africa.
LOS ANGELES, CA / ACCESSWIRE / June 5, 2017 / Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic ...